Israeli Experts Highlight Advances in Personalized Treatment for Rare Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL), a rare and complex subtype of non-Hodgkin lymphoma primarily affecting older adults, is undergoing a significant shift in treatment approaches in Israel. Dr. Netanel Horovitz, Deputy Director of Rambam Medical Center and Chair of the Israeli Hematology Association, explains that MCL typically presents in patients around their 60s and accounts for about 5%-7% of non-Hodgkin lymphoma cases. The disease often develops silently and is frequently diagnosed only after spreading beyond lymph nodes, complicating early detection.

Symptoms such as prolonged unexplained fever, significant weight loss (around 10% within six months), and severe night sweats should raise suspicion, though lymph node enlargement may be painless and unnoticed initially. Diagnosis involves lymph node biopsy, blood tests, imaging (CT or PET-CT), and sometimes bone marrow and molecular studies to assess disease aggressiveness and guide treatment.

Historically, treatment for MCL was aggressive, often involving intensive chemotherapy and autologous stem cell transplantation, suitable mainly for younger, healthier patients. However, Dr. Horovitz notes that this approach is not appropriate for all, especially those with comorbidities or older age. Advances now allow for personalized treatment plans based on genetic markers, such as TP53 mutations, which indicate a more aggressive disease less responsive to chemotherapy.

A major breakthrough is the introduction of BTK inhibitors, targeted biological drugs that block a key enzyme (Bruton tyrosine kinase) essential for cancer cell survival. These drugs, recently approved in Israel for first-line treatment, enable less toxic, more precise therapies. For some younger patients, BTK inhibitors may reduce or eliminate the need for stem cell transplantation, while older or high-risk patients benefit from combining these agents with other selective treatments.

Dr. Horovitz emphasizes that MCL requires ongoing monitoring and sometimes multiple treatment lines, but the current focus on early, targeted therapy reduces unnecessary chemotherapy exposure and better tailors care to individual patient profiles. This evolution marks a significant improvement in managing a disease once treated with a one-size-fits-all aggressive approach.